Effects of mirabegron on postoperative bladder perfusion in patients with non-muscle invasive bladder cancer
AIM To evaluate the efficacy and safety of mirabegron in improving postoperative bladder perfusion drug retention time and lower urinary tract symptoms in patients with non-muscle invasive bladder cancer(NMIBC).METHODS A total of 42 NMIBC patients who underwent transurethral resection of bladder tumor were selected and randomly divided into mirabegron group(mirabegron 50 mg qd),tolterodine group(tolterodine 2 mg bid),control group,and each group had 14 cases.The bladder perfusion drug retention time,overactive bladder syndrome score(OABSS),postvoid residual(PVR),maximum urine flow rate(Qmax)and the incidence of adverse reactions were observed in three groups after operation.RESULTS The bladder perfusion drug retention time and OABSS in the mirabegron group,tolterodine group were better than those in the control group within 4 weeks after operation(P＜0.05),and were similar within 8 weeks between the experiment groups(P＞0.05).The PVR in the mirabegron group was better than that in the tolterodine group within 8 weeks after operation(P＜0.05),and without statistically significant difference compared with the control group(P＞0.05).The Qmax in the mirabegron group was better than that in the tolterodine group within 2 weeks after operation(P＜0.05),and without statistically significant difference compared with the control group(P＞0.05).During the medication period,there were no adverse reactions such as dizziness or dry mouth in the mirabegron group,only one case of constipation occurred,and there was no significant difference compared to the control group(P＞0.05).CONCLUSION Mirabegron can improve postoperative bladder perfusion drug retention time and OABSS in patients with NMIBC,without increasing the incidence of adverse reactions.Furthermore,mirabegron has the higher safety without affecting bladder detrusor contraction during urination compared with tolterodine.
NETL
NSTL
万方数据
